Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006052 · ClinicalTrials.gov registry record · Phase 2
STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006052 is a Phase 2 study that has completed, run by Novartis.
The verdict
NCT00006052, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: STI571 may interfere with the growth of cancer cells and may be effective treatment for chronic myelogenous leukemia. PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have accelerated phase chronic myelogenous leukemia.
Interventions
- DRUG imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006052
The ClinicalTrials.gov registry entry for NCT00006052 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which imatinib mesylate is the first listed.
NCT00006052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006052 about?
NCT00006052 is a clinical study titled "STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia". RATIONALE: STI571 may interfere with the growth of cancer cells and may be effective treatment for chronic myelogenous leukemia. PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have accelerated phase chronic myelogenous leukemia.
What is the current status of trial NCT00006052?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-06.
What interventions are being tested in trial NCT00006052?
The interventions under investigation include: imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT00006052?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.